WebDevon J Shedlock is Chief Scientific Officer:Cell Therapies at Poseida Therapeutics Inc. See Devon J Shedlock's compensation, career history, education, & memberships. WebPoseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer. ... Devon J Shedlock’s Post ...
Devon J Shedlock on LinkedIn: Poseida Therapeutics …
WebChief Scientific Officer, Cell Therapy. Dr. Shedlock is our Chief Scientific Officer, Cell Therapy, after joining Poseida as our first employee in 2015 and most recently serving as Senior Vice President of Research & … WebHeading up the immuno-oncology research effort for Poseida at JLABS is Devon Shedlock, Ph.D., current Director of Immuno-Oncology at Poseida and the former Associate Director of the T-Cell Engineering Core that is part of Carl June's group at the University of Pennsylvania. ... Poseida is a therapeutics-focused biotechnology company … chipotle login okta
Prosecutor to dismiss charges against Atlanta police officers ... - CNN
WebAug 3, 2024 · "We are thrilled that Roche has embraced the opportunity to partner with us and use Poseida's unique allogeneic approach to develop CAR-T product candidates," said Devon J. Shedlock, Ph.D., Chief Scientific Officer, Cell Therapy at Poseida. "Using our proprietary technologies and manufacturing process including our booster molecule, we … WebAug 31, 2024 · Poseida's management team will host a conference call and webcast today, August 31, 2024 at 11:00am ET. The dial-in conference call numbers for domestic and international callers are (866) 939-3921 and (678) 302-3550, respectively. ... Presenter: Devon Shedlock, Ph.D., SVP Research & Development, Poseida Therapeutics. WebWe are thrilled to partner with Roche using Poseida’s unique allogeneic approach to develop novel CAR-T product candidates. With our proprietary technologies… 10 … chipotle login workday